News
Join our newsletter
Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update.
EpiVax Progresses on a Vaccine to Address SARS-CoV-2 Variants
PROVIDENCE, RI, November 30, 2021 /PRNewswire/...
EpiVax Collaborates with Leidos on Malaria Vaccine Research, Series of Papers Published in Frontiers In Immunology
PROVIDENCE, RI, November 2021 /PRNewswire/ --...
EpiVax Licenses Tregitope Technology to Maruho Co., Ltd. for development of Tregitope-based Therapies to Treat Autoimmune Condition
PROVIDENCE, RI, November 4, 2021 /PRNewswire/ --...
Immunogenicity Expert and FDA Alum Dr. Amy Rosenberg Joins EpiVax
PROVIDENCE, RI, July 6, 2021 /PRNewswire/ --...
EpiVax Identifies T cell Epitopes critical to robust T cell immune response in SARS-CoV-2 , Results Published in NPJ Vaccines
PROVIDENCE, RI, May 17, 2021 /PRNewswire/ --...
EpiVax Demonstrates Antigen-Specific Tolerance Induction in Allergy with Tregitopes, Results Published in Frontiers in Immunology
PROVIDENCE, RI, April 27, 2021 /PRNewswire/ --...
EpiVax Announces Participation in International Consortium for Development of Next-Generation Influenza Vaccines (INDIGO)
PROVIDENCE, RI, February 17, 2021 /PRNewswire/...
EpiVax Advances “PANDA” Peptide Therapeutic Immunogenicity Screening Program
PROVIDENCE, R.I., Dec. 29,...
EpiVax Reports Record Year for Immunogenicity Screening Toolkit (ISPRI)
PROVIDENCE, RI, December 15, 2020 /PRNewswire/...
FDA Awards $1.1M Contract to CUBRC and EpiVax for Validation of New Immunoinformatic Tool for Prospective Immunogenicity Assessment of Peptide Drugs and Their Impurities
PROVIDENCE, RI, October 22, 2020 /PRNewswire/ --...
Six months in, are we any closer to a vaccine?
Are we "Checking the Box" or Making Vaccines...
Press Release: EpiVax Announces Licensing of Immunogenicity Screening Toolkit, ISPRI, to AbCellera
PROVIDENCE, RI, June 8, 2020 /PRNewswire/ --...